Check back here often to see Cellecta’s event schedule. We are quite active in the scientific community.
May 2013
AACR Precision Medicine Series: Synthetic Lethal Approaches to Cancer Vulnerabilities (Poster)
May 17-20, Bellevue, WA
Poster Presentation:
“RNAi Genetic Screening for Drug Target Discovery”
Presented by: Dr. Paul Diehl, Director of Business Development
Genomics Research 2013 (Podium Presentation, Booth# 8, 2 Posters)
May 8-10, Boston, MA
Podium Presentation:
“Discovery of Cancer Drug Targets Using RNAi Screening with Pooled Lentiviral shRNA Libraries”
When: Thursday, May 9, 10:00 – 10:30AM
Presented by: Dr. Alex Chenchik, President/CEO/CSO
Poster Presentations:
“Pooled RNAi screens in xenograft mouse models”
Presented by: Dr. Alex Chenchik, President/CEO/CSO
“RNAi Genetic Screening for Drug Target Discovery”
Presented by: Dr. Paul Diehl, Director of Business Development
Exhibit Booth# 8
April 2013
BIO 2013 (One-to-one meetings)
April 22-25, Chicago, IL
AACR Annual Meeting 2013 (Spotlight Theater Presentation, Booth# 1258, 2 Posters)
April 6-10, Washington, D.C.
Add us to your AACR Itinerary online!
Spotlight Theater Presentation:
“Pooled RNAi Genetic Screening to Identify Critical Functional Genes and Novel Drug Targets”
When: Tuesday, April 9, 10:30 – 11:30AM
Where: Exhibit Hall A-C, Aisle 1100
Presented by: Dr. Paul Diehl, Director of Business Development
Summary: Phenotypic loss-of-function RNAi screens with pooled complex lentiviral-based shRNA expression libraries enables simultaneous screening of many thousands of transcripts to identify those that drive specific cellular responses. This approach has proven highly efficient, flexible, and cost-effective when it is integrated with quantitative next generation sequencing to accurately assay hairpin representation levels in cell populations screened using shRNA libraries. Recently, we have pushed the pooled RNAi screening method to the next step with an approach that allows us to construct pooled shRNA libraries which enable tracking of the clonal cell populations arising from each transduction in a pooled screen. This presentation will present results from in vitro “drop-out” screens to identify genes essential for cell viability and positive-selection screens. In addition, we will discuss approaches we are taking with our new clonal screening libraries to more difficult systems, such as ex-vivo xenograft models.
Poster Presentation:
“Pooled RNAi screens in xenograft mouse models”
When: Tuesday, April 9, 8:00AM – 12:00PM
Where: Section 33, Poster Board 12, Abstract 3172
Presented by: Dr. Donato Tedesco, Lead Research Scientist
Abstract: We present results of clonal analysis studies aimed at characterizing the heterogeneity of in vivo cancer cell growth in xenograft models. Using a high-throughput sequencing method, we followed the fate of thousands of individually bar-coded cancer cells grown in vitro, or in vivo upon sub-cutaneous implantation in immunocompromised mice. By precisely and reproducibly quantifying clonal cancer cell growth in vivo, we found that xenograft growth is marked by a phenomenon of clonal dominance, in which a small subset of cancer cell sub-clones account for the bulk of the resulting tumor mass. This phenomenon has important implications for the field of in vivo shRNA screening. Subsequently, we developed a new proprietary clonal RNAi screening platform specifically designed to circumscribe the clonal dominance effect in xenograft model viability screens.
We used this technology to perform xenograft “drop-out” screens in a panel of tumorigenic cell lines, including human breast, ovarian and colon carcinomas. Preliminary data will be presented. These results demonstrate that complex pooled shRNA libraries provide a highly efficient, flexible, and unique tool for in vivo screens aimed the discovery of potential cancer therapy targets.
Poster Presentation:
“Open-source RNAi genetic screen platform: Discovery of drug targets in cancer cell models”
When: Tuesday, April 9, 8:00AM – 12:00PM
Where: Section 32, Poster Board 28, Abstract 3160
Presented by: Dr. Paul Diehl, Director of Business Development
Abstract: We have developed an open-source RNAi genetic screening technology, funded in part by NIH grants and freely available to the scientific community. This platform can be used for functional discovery of drug targets associated with viability and regulation of signaling pathways in cancer cells. Here we present a novel, free public resource for genome-wide RNAi screens: DECIPHER pooled lentiviral shRNA libraries. Results are shown from two RNAi screens with DECIPHER shRNA libraries: one “drop-out” screen to identify genes essential for viability in a panel of leukemic cells, and a second “rescue” screen to identify genes required for FAS induced apoptosis.
Both screens found a combination of known and novel signaling pathway and regulatory genes whose functions were confirmed to be required to produce the biological responses. From the viability screens in the panel of leukemia cell lines, subsequent validation using single shRNA-expressing constructs showed that about 80% of the shRNAs identified in each complex library screen did in fact lead to cell death when transduced in cells. Analysis of the identified essential genes for known biological interactions revealed non-random clusters of interacting proteins that provide a useful strategy for prioritization of potential targets. Analysis of the lethal combinations indicates redundant, complementary, and compensatory responses in cancer cells. In the case of the FAS-induced apoptosis, in vitro screening data also enabled us to select targets that protected mice from FAS-induced hepatic failure.
These results demonstrate that complex pooled shRNA libraries provide a highly efficient, flexible, and cost-effective alternative to array-based RNAi screening methods for identifying genes regulating biological responses and possible new therapeutic targets.
Exhibit Booth# 1258, centrally located, next to the food court
March 2013
RNAi Oxford 2013 (Talk, Poster)
March 19-21, Oxford, UK
Podium Presentation:
“Pooled RNAi Genetic Screening to Identify Critical Functional Genes and Novel Drug Targets”
Presented by: Dr. Paul Diehl, Director of Business Development
Poster Presentation:
“Pooled RNAi Genetic Screening to Identify Critical Functional Genes and Novel Drug Targets”
Presented by: Dr. Paul Diehl, Director of Business Development
BIO-Europe Spring 2013 (One-to-one meetings)
March 11-13, Barcelona, Spain
CONPO 2013, Controversies in Personal Oncology (Talk, Poster)
March 7-10, Barcelona, Spain
Podium Presentation:
“Moving Beyond In Vitro Models: Addressing the Challenges of Pooled RNAi Screens in Xenografts”
Presented by: Dr. Paul Diehl, Director of Business Development
Poster Presentation:
“Moving Beyond In Vitro Models: Addressing the Challenges of Pooled RNAi Screens in Xenografts”
Presented by: Dr. Paul Diehl, Director of Business Development
February 2013
Ninth AACR-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research (2 Posters)
February 21-25, Maui, HI
Poster Presentations:
“Discovery of cancer drug targets in in vitro and in vivo using pooled shRNA libraries”
Presented by: Dr. Alex Chenchik, President/CEO/Research Director
“RNAi Genetic Screening for Drug Target Discovery”
Presented by: Karim Hyder, Director of Operations
MMTC 2013, Molecular Medicine Tri-Conference (Poster, Exhibit# 613)
February 11-15, San Francisco, CA
Poster Presentation:
“RNAi Screening for Drug Target Discovery”
Presented by: Dr. Paul Diehl, Director of Business Development
December 2012
ASCB Annual Meeting 2012 (Tutorial, Exhibit# 536, Poster)
December 15-19, San Francisco, CA
“Finding Functional Driver Genes Using RNAi Genetic Screening with Pooled Genome-Wide Libraries”
When: Monday, Dec. 17th, 6:45-8:15pm, room 112 (Tutorial C)
Presented by: Dr. Paul Diehl, Director of Business Development
Poster Presentation:
“Discovery of cancer drug targets using RNAi screening with pooled lentiviral shRNA libraries”
When: Sunday, Dec. 16th, 2:00-3:30pm; Halls A-C; presentation# 856; Board# B1412
Presented by: Dr. Paul Diehl, Director of Business Development
October 2012
Discovery on Target 2012 (Speaker, Panel Member, Exhibit# 20, Poster)
October 1-3, Boston, MA
Track: Functional Genomics Screening Strategies
“Discovery of Cancer Drug Targets using RNAi Screening with Pooled Lentiviral shRNA Libraries”
When: Tuesday, Oct. 2, 4:15 – 4:45 pm
Presented by: Dr. Paul Diehl, Director of Business Development
Panel Discussion:
“TECHNOLOGY PANEL: What Improvements Can We Expect in Functional Genomics Screens Going Forward?”
When: Wednesday, Oct. 3, 11:55 am
Moderator: Christophe Echeverri, Ph.D., CEO & CSO, Cenix BioScience
Panelists: Abhishek Saharia, Ph.D., Global Product Manager, Functional Genomics, Sigma Aldrich
Paul Diehl, Ph.D., Director, Business Development, Cellecta, Inc.
Queta Smith, Ph.D., Associate Director, Customer Care, Thermo Fisher Scientific Inc.
Poster Presentation:
“Discovery of Cancer Drug Targets using RNAi Screening with Pooled Lentiviral shRNA Libraries”
Presented by: Dr. Paul Diehl, Director of Business Development
September 2012
The EMBO Meeting 2012 (Speaker, Poster)
September 22-25, Nice, France
“Discovery of Cancer Drug Targets using RNAi Screening with Pooled Lentiviral shRNA Libraries”
When: Wednesday, Sept. 24, 14:15 – 14:45, Room Rhodes 6
Presented by: Dr. Paul Diehl, Director of Business Development
Poster Presentation:
“Discovery of Cancer Drug Targets using RNAi Screening with Pooled Lentiviral shRNA Libraries”
Presented by: Dr. Paul Diehl, Director of Business Development
Academic Screening Workshop 2012 (Speaker, Poster)
September 20-21, Baltimore, MD
“RNAi Screening for Anti-Cancer Targets with Pooled High Complexity shRNA Libraries”
When: Tuesday, Sept. 20, 14:30
Presented by: Dr. Donato Tedesco, Lead Research Scientist
Poster Presentation:
“RNAi Screening for Anti-Cancer Targets with Pooled High Complexity shRNA Libraries”
Presented by: Dr. Donato Tedesco, Lead Research Scientist
EMBO Workshop: The reciprocal interactions of signaling pathways and non-coding RNA (Invited Speaker, Poster)
September 16-19, Monte Verita, Ascona, Switzerland
“Control of epigenetic silencing of repeats and non-coding RNAs by p53″
When: Tuesday, Sept. 18, 10:15 – 10:30
Presented by: Dr. Alex Chenchik, President/CEO/CSO
Poster Presentation:
“Control of epigenetic silencing of repeats and non-coding RNAs by p53″
Presented by: Dr. Alex Chenchik, President/CEO/CSO
Poster Presentation:
“Genome-Wide Identification and Functional Analysis of Non-Coding RNAs in Cancer Models”
Presented by: Dr. Paul Diehl, Director of Business Development
Genomics Research Europe 2012, RNAi and miRNA track (Invited Speaker, Poster)
September 4-5, Frankfurt, Germany
“Discovery of Cancer Drug Targets using RNAi Screening with Pooled Lentiviral shRNA Libraries”
When: Wednesday, Sept. 5, 14:45 – 15:15
Presented by: Dr. Alex Chenchik, President/CEO/CSO
Poster Presentation:
“Discovery of Cancer Drug Targets using RNAi Screening with Pooled Lentiviral shRNA Libraries”
Presented by: Dr. Alex Chenchik, President/CEO/CSO
August 2012
Next Generation Sequencing and Data Analysis (Poster)
August 13-15, Providence, RI
Poster Presentation:
“RNAi Genetic Screening for Drug Target Discovery”
Presented by: Mikhail Makhanov, Research Scientist, Bioinformatics
July 2012
Gordon Cell Death, 2012 (Poster)
July 15-20, Lucca (Barga), Italy
Poster Presentation:
“Viability Screens with Pooled Lentiviral shRNA Libraries”
Presented by: Alex Chenchik, President/CEO/CSO
June 2012
2012 BIO International Convention (Partnering)
June 18-21, Boston, MA
May 2012
GTC 3rd RNAi Research & Therapeutics Conference, Omics Evolution Summit 2012 (Exhibit, Speaker, Poster)
May 29-31, Boston, MA
“RNAi Genetic Screening for Drug Target Discovery”
When: Thursday, May 31, 10:15 – 10:40 am
Presented by: Dr. Paul Diehl, Director of Business Development
Poster Presentation:
“RNAi Genetic Screening for Drug Target Discovery”
Presented by: Dr. Paul Diehl, Director of Business Development
April 2012
BIO-IT World 2012 (Poster)
April 24-26, Boston, MA
Poster Presentation:
“RNAi Genetic Screening for Drug Target Discovery”
Presented by: Mikhail Makhanov, Research Scientist, Bioinformatics
Genomics Research 2012 (Exhibit# 2, Invited Speaker, Poster)
April 19-20, Boston, MA
“RNAi Genetic Screening for Drug Target Discovery”
When: Thursday, April 19, 12:15 – 12:45 pm
Presented by: Dr. Alex Chenchik, President/CEO/CSO
Poster Presentation:
“RNAi Genetic Screening for Drug Target Discovery: Viability screens in leukemic and breast cancer cells using Open Source pooled lentiviral shRNA libraries”
Presented by: Dr. Alex Chenchik, President/CEO/CSO
March 2012
AACR Annual Meeting, 2012 (Exhibit# 2815, Poster)
March 31 – April 4, 2012, Chicago, IL
Add to My AACR Show Planner
Poster Presentation:
“RNAi Genetic Screening for Drug Target Discovery”
Add to My AACR Itinerary at aacr.org
When: Sunday, April 01, 2012, 1:00 pm – 5:00 pm
Poster: PO.ET03.05. New Models, Screens, and Diagnostics for Target Identification
McCormick Place West (Hall F), Section 33, Poster 3
Presented by: Dr. Alex Chenchik, President/CEO/CSO
Targets and Tools 2012, Oncology Drug Discovery (Talk, Poster)
Mar 20-21, 2012, Berlin, Germany
“RNAi Genetic Screening for Drug Target Discovery”
When: Tuesday, Mar. 20, 12:45 – 1:15pm
Presented by: Dr. Paul Diehl, Director of Business Development
Poster Presentation:
“RNAi Genetic Screening for Drug Target Discovery”
Presented by: Dr. Paul Diehl, Director of Business Development
February 2012
SLAS 2012 (Exhibit# 648, Invited Speaker, Poster)
Feb 4-8, 2012, San Diego, CA
Podium Presentation:
“Viability screens in leukemic and breast cancer cells with pooled lentiviral shRNA libraries identify potential therapeutic targets and synergistic lethal interactions.”
When: Tuesday, Feb. 7, 4:30 – 5:00pm
Where: SDCC, Ballroom 6C
Session: RNAi Screening Technologies
Presented by: Dr. Alex Chenchik, President/CEO/CSO
Read the abstract and add it to your calendar, via www.slas2012.org
Poster Presentation:
“HT Screening for bioactive peptides that increase radiation tolerance using a pooled lentiviral peptide scanning library.”
When: Tuesday, Feb. 7, 1:00 – 3:00pm
Poster Sequence #: TP120
Track Title: Track 3 – High Throughput Technologies
Presented by: Dr. Alex Chenchik
December 2011
ASCB 2011 (Exhibit# 901, Tutorial, Poster)
Dec 3-7, 2011, Denver, CO
“Open-Source RNAi Genetic Screen Platform: Discovery of Drug Targets in Cancer Cell Models”
When: Monday, Dec. 5, 6:45 – 8:15pm
Where: Room 109
Hors D’oeuvres and light dinner buffet
Presented by: Dr. Paul Diehl
Poster Presentation:
“Viability screens in cancer cells with pooled shRNA libraries identify potential therapeutic targets and synergistic lethal interactions.”
When: Tuesday, Dec. 6, 2:00 – 3:30pm
Where: Board #B862, Exhibit Hall ABEF, Presentation# 1895
Presented by: Karim Hyder
November 2011
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics(Poster)
Nov 12-16, 2011, San Francisco, CA
Poster Presentation:
“Identification of potential cancer drug targets using HT RNAi screening with pooled shRNA libraries”
Zing Cancer Conference 2011 (Poster)
Nov 9-13, 2011, Xcaret, Mexico
Poster Presentation:
“Viability screens in cancer cells with pooled shRNA libraries identify potential therapeutic targets and synergistic lethal interactions”
NCRI Cancer Conference (Poster)
Nov 6-9, 2011, Liverpool, England
Poster Presentation:
“Viability screens in cancer cells with pooled shRNA libraries identify potential therapeutic targets and synthetic lethal interactions”
Where: Poster# 162
Presented by: Dr. Paul Diehl
Discovery on Target 2011 (Exhibit# 6)
Nov 2-4, 2011, Boston, MA
October 2011
The 6th Annual Peptide Therapeutics Symposium (Poster)
Oct 20-21, 2011, Salk Institute, La Jolla, CA
Poster Presentation:
“HT Screening for bioactive peptides that increase radiation tolerance using a pooled lentiviral peptide scanning library”
AACR Translation of the Cancer Genome: Scientific, Clinical, and Operational Challenges (Talk, Poster)
Oct 15-18, 2011, San Francisco, CA
Poster Presentation:
“Viability screens in leukemic and breast cancer cells with pooled lentiviral shRNA libraries identify potential therapeutic targets and synergistic lethal interactions”
12th International Congress of Human Genetics (ICHG) and the 61st ASHG Annual Meeting (Exhibit# 1425, Workshop, Poster)
Oct 11-15, 2011, Quebec, Canada
“Open-Source RNAi Genetic Screen Platform: Discovery of Drug Targets in Cancer Cell Models”
When: Friday, Oct. 14, 12:30 – 2:00pm
Where: Room 523, Level 5
Presented by: Dr. Paul Diehl
Link to ICHG/ASHG Schedule
Poster Presentation:
“Viability Screens with Pooled shRNA Libraries Identify Novel and Synthetically Lethal Anti-Cancer Targets”
When: Wednesday, Oct. 12, 3:00 – 4:00pm
Where: Poster #1210W, Level 2
Presented by: Dr. Paul Diehl
Academic Screening Workshop (Panel, Poster)
Oct 6-7, 2011 – Bridgewater, NJ
Panel: RNAi Technologies, Alex Chenchik, Cellecta, Inc.
Poster Presentation:
“Viability Screens with Pooled shRNA Libraries Identify Novel and Synthetically Lethal Anti-Cancer Targets”
September 2011
AACR Frontiers in Basic Cancer Research (Poster)
Sept 15-18, 2011, San Francisco, CA
Poster Presentation:
“Viability Screens with Pooled shRNA Libraries Identify Novel and Synthetically Lethal Anti-Cancer Targets”
Where: Poster #A36
Presented by: Dr. Kyle Bonneau
Sept 10-13, 2011 – The EMBO Meeting (Poster)
Our President/CEO presents poster #C194 on “Viability screens in cancer cells with pooled shRNA libraries identify potential therapeutic targets and synergistic lethal interactions” in Vienna, Austria.
Sept 8-9, 2011 – RNAi Europe (Poster)
Our President/CEO presents a poster on “Identification of potential cancer drug targets using HT RNAi screening with pooled shRNA libraries” in Munich, Germany.
August 2011
Aug 3, 2011 – Illumina Bay Area User Group Meeting (PDF)
June 2011
June 27-30, 2011 – BIO 2011 International Convention
Meet with our President/CEO and Director of Business Development at BIO 2011.
May 2011
May 15-21, 2011 – Gordon Conference – Antimicrobial Peptides (Poster)
Our President/CEO presents a poster on HT Screening for Bioactive Peptides that confer Radiation Resistance at the Gordon Conference in Barga, Italy.
May 2-3, 2011 – Stanford CCSB Annual Symposium (Poster)
Our President/CEO presents findings from RNAi screening for cancer drug targets at the Stanford CCSB Annual Symposium on Systems Biology of Cancer.
April 2011
Apr 28-29, 2011 – 6th Annual SBIR ASSETs Forum (Poster)
Cellecta presents its capabilities at the 6th Annual SBIR ASSETs Forum in Boston.
Apr 26-27, 2011 – RNAi World Congress (Poster)
Cellecta presents Poster #103 at the RNAi World Congress in Boston.
Apr 20, 2011 – Abbott/UMass Vendor Show (Seminar, Poster)
Cellecta exhibits and gives a seminar at the Abbott Pharmaceuticals/UMass Medical School Vendor Show.
Apr 12-14, 2011 – BioTrinity 2011
At the BioTrinity Partnering Conference in the UK, we meet with potential partners.
Apr 02-06, 2011 – AACR 2011 (Exhibit, Poster)
Cellecta has an exhibit booth and presents a poster at AACR 2011 in Orlando, FL.
March 2011
Mar 27-31, 2011 – SBS 2011 (Talk, Exhibit, Tutorial, Poster)
Cellecta presents a talk, tutorial, and poster, and has an exhibit booth at SBS 2011 in Orlando, FL.
Mar 14-16, 2011 – BIO-Europe Spring 2011
Our Director of Business Development met with potential partners at BIO-Europe Spring in Milan, Italy.
